Kitov gains on positive preclinical cancer med data

Thinly traded nano cap Kitov Pharma (KTOV +59.6%) is up on a healthy 36x surge in volume in response to encouraging preclinical data on cancer candidate NT219, a novel small molecule cancer drug that fights cancer by activating the “OFF” switch in major oncogenic pathways.

Collaborators at Hebrew University showed that NT219 binds directly to two known modulators of tumor survival, metastasis and drug resistance. The data also showed that short exposure of cancer cells to NT219 triggered irreversible shutdown of these pathways, producing a long-term anti-cancer effect.

https://seekingalpha.com/news/3423113-kitov-60-percent-encouraging-nt219-data